| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J Inserte, A Najib, P Pelliccioni, C Gil, J Aguiler. Inhibition by tetanus toxin of sodium-dependent, high-affinity [3H]5-hydroxytryptamine uptake in rat synaptosomes. Biochemical pharmacology. vol 57. issue 1. 1999-02-11. PMID:9920291. |
serotonin transport inhibitors such as fenfluramine (ic50, 11.0 +/- 0.9 microm), paroxetine (ic50, 33.5 +/- 0.1 microm), and imipramine (ic50, 89.9 +/- 5.7 microm) were 3 or 4 orders of magnitude less potent than tetx (ic50, 8.7 +/- 1.0 nm). |
1999-02-11 |
2023-08-12 |
rat |
| Z Nahas, K A Arlinghaus, K J Kotrla, R R Clearman, M S Georg. Rapid response of emotional incontinence to selective serotonin reuptake inhibitors. The Journal of neuropsychiatry and clinical neurosciences. vol 10. issue 4. 1999-02-05. PMID:9813792. |
ei improved dramatically with three different selective serotonin reuptake inhibitors (fluoxetine, sertraline, and paroxetine) in the context of these different cns diseases. |
1999-02-05 |
2023-08-12 |
Not clear |
| L P Shearman, A M McReynolds, F C Zhou, J S Meye. Relationship between [125I]RTI-55-labeled cocaine binding sites and the serotonin transporter in rat placenta. The American journal of physiology. vol 275. issue 6. 1999-02-03. PMID:9843724. |
[3h]paroxetine binding and immunocytochemical staining for serotonin [5-hydroxytryptamine (5-ht)] and for the 5-ht transporter were also used to obtain evidence for rat placental 5-ht uptake. |
1999-02-03 |
2023-08-12 |
rat |
| L P Shearman, A M McReynolds, F C Zhou, J S Meye. Relationship between [125I]RTI-55-labeled cocaine binding sites and the serotonin transporter in rat placenta. The American journal of physiology. vol 275. issue 6. 1999-02-03. PMID:9843724. |
the presence of a rat placental 5-ht uptake system was additionally supported by the [3h]paroxetine binding experiments and by the presence throughout the placenta of immunoreactivity for 5-ht and the 5-ht transporter. |
1999-02-03 |
2023-08-12 |
rat |
| P Bauman. Care of depression in the elderly: comparative pharmacokinetics of SSRIs. International clinical psychopharmacology. vol 13 Suppl 5. 1999-01-28. PMID:9817619. |
citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline are the selective serotonin reuptake inhibiting antidepressants available. |
1999-01-28 |
2023-08-12 |
Not clear |
| P Bauman. Care of depression in the elderly: comparative pharmacokinetics of SSRIs. International clinical psychopharmacology. vol 13 Suppl 5. 1999-01-28. PMID:9817619. |
in these patients, depending on the selective serotonin reuptake inhibitor (ssri) used, it is recommended to adapt the dose of the antidepressant: lower doses should be used for citalopram, paroxetine and probably also for sertraline, when therapy is initiated. |
1999-01-28 |
2023-08-12 |
Not clear |
| P J Goodnick, B J Goldstei. Selective serotonin reuptake inhibitors in affective disorders--I. Basic pharmacology. Journal of psychopharmacology (Oxford, England). vol 12. issue 3 Suppl B. 1999-01-15. PMID:9808077. |
the selective serotonin reuptake inhibitors (ssris), citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline, are the result of rational research to find drugs that were as effective as the tricyclic antidepressants but with fewer safety and tolerability problems. |
1999-01-15 |
2023-08-12 |
Not clear |
| C L DeVan. Differential pharmacology of newer antidepressants. The Journal of clinical psychiatry. vol 59 Suppl 20. 1999-01-11. PMID:9881541. |
following the introduction in 1988 of the first serotonin selective reuptake inhibitor (ssri) in the united states, the options have expanded and now include four ssris (fluoxetine, sertraline, paroxetine, fluvoxamine), nefazodone, venlafaxine, and mirtazapine. |
1999-01-11 |
2023-08-12 |
Not clear |
| E O'Shea, R Granados, B Esteban, M I Colado, A R Gree. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology. vol 37. issue 7. 1999-01-07. PMID:9776387. |
of mdma produced immediate dose-related hyperthermia and a dose-related decrease in 5-ht, 5-hydroxyindoleacetic acid (5-hiaa) and [3h]paroxetine binding in regions of the brain 7 days later, with a dose of 4 mg/kg having no degenerative effect. |
1999-01-07 |
2023-08-12 |
rat |
| E M Clement, D G Grahame-Smith, J M Elliot. Investigation of the presynaptic effects of quinine and quinidine on the release and uptake of monoamines in rat brain tissue. Neuropharmacology. vol 37. issue 7. 1999-01-07. PMID:9776390. |
the inhibition of [3h]5-ht uptake by quinine and quinidine was competitive in nature and corresponded with the potencies of these drugs to inhibit [3h]paroxetine binding. |
1999-01-07 |
2023-08-12 |
rat |
| N Haddjeri, P Blier, C de Montign. Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 18. issue 23. 1998-12-18. PMID:9822768. |
however, after long-term treatment with the tricyclic antidepressant imipramine, the selective 5-ht reuptake inhibitor paroxetine, the reversible monoamine oxidase-a inhibitor befloxatone, the alpha2-adrenergic antagonist mirtazapine, or the 5-ht1a receptor agonist gepirone or multiple electroconvulsive shock (ecs) administration, way 100635 markedly increased (60-200%) the firing activity of ca3 pyramidal neurons. |
1998-12-18 |
2023-08-12 |
rat |
| T Vermeule. Distribution of paroxetine in three postmortem cases. Journal of analytical toxicology. vol 22. issue 6. 1998-12-17. PMID:9788532. |
paroxetine (paxil) is a selective serotonin reuptake inhibitor, one of a new class of antidepressants used in the treatment of obsessive-compulsive disorder, panic disorder, and depression. |
1998-12-17 |
2023-08-12 |
Not clear |
| T Vermeule. Distribution of paroxetine in three postmortem cases. Journal of analytical toxicology. vol 22. issue 6. 1998-12-17. PMID:9788532. |
paroxetine potentiates serotonergic activity through the selective inhibition of serotonin reuptake in the central nervous system. |
1998-12-17 |
2023-08-12 |
Not clear |
| C Davidson, J A Stamfor. Contrasting effects of chronic paroxetine on 5-HT1A control of dorsal raphe cell firing and 5-HT release. Neuroreport. vol 9. issue 11. 1998-11-18. PMID:9721928. |
contrasting effects of chronic paroxetine on 5-ht1a control of dorsal raphe cell firing and 5-ht release. |
1998-11-18 |
2023-08-12 |
Not clear |
| C Davidson, J A Stamfor. Contrasting effects of chronic paroxetine on 5-HT1A control of dorsal raphe cell firing and 5-HT release. Neuroreport. vol 9. issue 11. 1998-11-18. PMID:9721928. |
chronic paroxetine did not, however, desensitize the 5-ht1a receptors controlling 5-ht release but increased the 8-oh-dpat emax from 54.9% to 79.2% inhibition of 5-ht release. |
1998-11-18 |
2023-08-12 |
Not clear |
| M T Lambert, C Trutia, F Pett. Extrapyramidal adverse effects associated with sertraline. Progress in neuro-psychopharmacology & biological psychiatry. vol 22. issue 5. 1998-11-18. PMID:9723116. |
extrapyramidal adverse effects have been reported with the selective serotonin re-uptake inhibitor (ssri) antidepressants, particularly fluoxetine and paroxetine. |
1998-11-18 |
2023-08-12 |
Not clear |
| I Hindmarc. The behavioural toxicity of antidepressants: effects on cognition and sexual function. International clinical psychopharmacology. vol 13 Suppl 6. 1998-11-18. PMID:9728668. |
some selective serotonin reuptake inhibitors (ssris; paroxetine and sertraline) are associated with behavioural activation that is also responsible for an impairment of sexual function. |
1998-11-18 |
2023-08-12 |
Not clear |
| P Schloss, D C William. The serotonin transporter: a primary target for antidepressant drugs. Journal of psychopharmacology (Oxford, England). vol 12. issue 2. 1998-11-06. PMID:9694022. |
imipramine) which also block noradrenaline reuptake, highly specific serotonin reuptake inhibitors (ssris) such as fluoxetine and paroxetine have been developed, which are increasingly prescribed for depressed patients. |
1998-11-06 |
2023-08-12 |
Not clear |
| M B Tome, M T Isaa. Cost effectiveness study of a year follow-up of selective serotonin reuptake inhibitor (SSRI) and augmentor combination compared with SSRI and placebo. International clinical psychopharmacology. vol 13. issue 4. 1998-11-02. PMID:9727728. |
patients received the selective serotonin reuptake inhibitor (ssri) antidepressant paroxetine and an augmenting agent (pindolol) or placebo. |
1998-11-02 |
2023-08-12 |
Not clear |
| M D Waldinger, M W Hengeveld, A H Zwinderman, B Olivie. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of clinical psychopharmacology. vol 18. issue 4. 1998-10-28. PMID:9690692. |
the first double-blind, placebo-controlled study was conducted in men with lifelong rapid ejaculation and aimed to assess putative differences between the major selective serotonin reuptake inhibitors (ssris) (fluoxetine, fluvoxamine, paroxetine, and sertraline) with regard to their ejaculation-delaying effect. |
1998-10-28 |
2023-08-12 |
Not clear |